Phase I study of gemcitabine given weekly as a short infusion for non-small cell lung cancer: results and possible immune system-related mechanisms.
Levitt ML, Kassem B, Gooding WE, Miketic LM, Landreneau RJ, Ferson PF, Keenan R, Yousem SA, Lindberg CA, Trenn MR, Ponas RS, Tarasoff P, Sabatine JM, Friberg D, Whiteside TL.
Levitt ML, et al. Among authors: gooding we.
Lung Cancer. 2004 Mar;43(3):335-44. doi: 10.1016/j.lungcan.2003.09.011.
Lung Cancer. 2004.
PMID: 15165093
Clinical Trial.